The combination of chemotherapy with immune response modifiers such as interleukin 2 (IL-2) or interferon-α (IFN-α), referred to as chemo-immunotherapy, has shown promising anti-tumor activity to melanoma [22], [23]. The gene discussed is IL2; the disease is melanoma.